BR112023016083A2 - Composições contendo análogos de incretina e seus usos - Google Patents
Composições contendo análogos de incretina e seus usosInfo
- Publication number
- BR112023016083A2 BR112023016083A2 BR112023016083A BR112023016083A BR112023016083A2 BR 112023016083 A2 BR112023016083 A2 BR 112023016083A2 BR 112023016083 A BR112023016083 A BR 112023016083A BR 112023016083 A BR112023016083 A BR 112023016083A BR 112023016083 A2 BR112023016083 A2 BR 112023016083A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions containing
- glucagon
- composition
- relates
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 title abstract 3
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 2
- 108060003199 Glucagon Proteins 0.000 abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 2
- 229960004666 glucagon Drugs 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000012929 tonicity agent Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
composições contendo análogos de incretina e seus usos. a presente invenção refere-se a uma composição que inclui um análogo de incretina com atividade nos receptores do polipeptídeo insulinotrópico dependente de glicose (gip), do peptídeo semelhante ao glucagon 1 (glp-1) e do glucagon (gcg) (ou seja, agonista triplo de receptor) e um ou mais agentes adicionais como um agente de tonicidade e um conservante. a presente invenção refere-se também a métodos para tratar doenças como diabetes mellitus tipo 2, dislipidemia, síndrome metabólica, doença hepática gordurosa não alcoólica, esteato-hepatite não alcoólica e obesidade com a composição.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164702P | 2021-03-23 | 2021-03-23 | |
| PCT/US2022/021309 WO2022204117A1 (en) | 2021-03-23 | 2022-03-22 | Incretin analog-containing compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016083A2 true BR112023016083A2 (pt) | 2023-10-03 |
Family
ID=81580297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016083A BR112023016083A2 (pt) | 2021-03-23 | 2022-03-22 | Composições contendo análogos de incretina e seus usos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240173250A1 (pt) |
| EP (1) | EP4312982A1 (pt) |
| JP (1) | JP2024513754A (pt) |
| KR (1) | KR20230146645A (pt) |
| CN (1) | CN117042754A (pt) |
| AR (1) | AR125086A1 (pt) |
| AU (1) | AU2022246002A1 (pt) |
| BR (1) | BR112023016083A2 (pt) |
| CA (1) | CA3213230A1 (pt) |
| CL (1) | CL2023002808A1 (pt) |
| CO (1) | CO2023012373A2 (pt) |
| CR (1) | CR20230452A (pt) |
| DO (1) | DOP2023000200A (pt) |
| EC (1) | ECSP23071867A (pt) |
| IL (1) | IL305688A (pt) |
| MX (1) | MX2023011278A (pt) |
| PE (1) | PE20240238A1 (pt) |
| TW (2) | TW202423476A (pt) |
| WO (1) | WO2022204117A1 (pt) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101193652B (zh) * | 2005-04-08 | 2011-11-02 | 安米林药品公司 | 包含肠降血糖素肽和非质子极性溶剂的药物制剂 |
| JO2945B1 (en) * | 2006-09-13 | 2016-03-15 | سميث كلاين بيتشام كوربوريشن | Methods of giving prolonged hypoglycemic agents |
| UA101304C2 (ru) * | 2006-09-13 | 2013-03-25 | Смитклайн Бичам Корпорейшн | Способы введения гипогликемических средств продленного действия |
| ES2484266T3 (es) | 2010-03-01 | 2014-08-11 | Eli Lilly And Company | Dispositivo de inyección automático con mecanismo de retardo incluyendo un elemento de empuje de función doble |
| WO2012025921A1 (en) * | 2010-08-23 | 2012-03-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions for gastric delivery of active agents |
| JP6165168B2 (ja) * | 2011-12-22 | 2017-07-19 | ファイザー・インク | 抗糖尿病化合物 |
| CN104736558A (zh) * | 2012-09-07 | 2015-06-24 | 赛诺菲 | 用于治疗代谢综合征的融合蛋白 |
| WO2018213151A1 (en) * | 2017-05-18 | 2018-11-22 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation comprising incretin-insulin conjugates |
| TWI767095B (zh) | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI744579B (zh) | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| EP3827015A1 (en) * | 2018-07-23 | 2021-06-02 | Eli Lilly and Company | Gip/glp1 co-agonist compounds |
-
2022
- 2022-03-15 AR ARP220100594A patent/AR125086A1/es unknown
- 2022-03-15 TW TW113107533A patent/TW202423476A/zh unknown
- 2022-03-15 TW TW111109488A patent/TWI837615B/zh active
- 2022-03-22 CA CA3213230A patent/CA3213230A1/en active Pending
- 2022-03-22 CR CR20230452A patent/CR20230452A/es unknown
- 2022-03-22 CN CN202280023411.5A patent/CN117042754A/zh active Pending
- 2022-03-22 MX MX2023011278A patent/MX2023011278A/es unknown
- 2022-03-22 AU AU2022246002A patent/AU2022246002A1/en active Pending
- 2022-03-22 KR KR1020237032194A patent/KR20230146645A/ko active Search and Examination
- 2022-03-22 US US18/552,013 patent/US20240173250A1/en active Pending
- 2022-03-22 BR BR112023016083A patent/BR112023016083A2/pt unknown
- 2022-03-22 WO PCT/US2022/021309 patent/WO2022204117A1/en active Application Filing
- 2022-03-22 EP EP22721153.9A patent/EP4312982A1/en active Pending
- 2022-03-22 JP JP2023558406A patent/JP2024513754A/ja active Pending
- 2022-03-22 IL IL305688A patent/IL305688A/en unknown
- 2022-03-22 PE PE2023002682A patent/PE20240238A1/es unknown
-
2023
- 2023-09-19 CO CONC2023/0012373A patent/CO2023012373A2/es unknown
- 2023-09-20 DO DO2023000200A patent/DOP2023000200A/es unknown
- 2023-09-21 CL CL2023002808A patent/CL2023002808A1/es unknown
- 2023-09-22 EC ECSENADI202371867A patent/ECSP23071867A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230452A (es) | 2023-10-11 |
| CA3213230A1 (en) | 2022-09-29 |
| TW202302139A (zh) | 2023-01-16 |
| DOP2023000200A (es) | 2023-10-15 |
| PE20240238A1 (es) | 2024-02-16 |
| TW202423476A (zh) | 2024-06-16 |
| AR125086A1 (es) | 2023-06-07 |
| AU2022246002A1 (en) | 2023-08-24 |
| CO2023012373A2 (es) | 2023-09-29 |
| MX2023011278A (es) | 2023-10-04 |
| IL305688A (en) | 2023-11-01 |
| TWI837615B (zh) | 2024-04-01 |
| CL2023002808A1 (es) | 2024-06-21 |
| KR20230146645A (ko) | 2023-10-19 |
| WO2022204117A1 (en) | 2022-09-29 |
| JP2024513754A (ja) | 2024-03-27 |
| EP4312982A1 (en) | 2024-02-07 |
| US20240173250A1 (en) | 2024-05-30 |
| CN117042754A (zh) | 2023-11-10 |
| ECSP23071867A (es) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ravassa et al. | Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes | |
| BR112022023834A2 (pt) | Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo | |
| BR112017008160A8 (pt) | Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição | |
| EA202091290A1 (ru) | Аналоги инкретина и их применение | |
| CL2021002649A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| CO2017006737A2 (es) | Análogos de gip y glp-1 en donde la lisina (k) en la posición 20 está químicamente modificada a través de la conjugación al grupo épsilon-amino de la cadena lateral k con ([2-(2-amino-etoxi)-etoxi]-acetil)2-(γglu)a-co-(ch2)b-co2h activos como agonistas de receptores gip y gip-1 | |
| BR112022009396A2 (pt) | Análogos de incretina e usos dos mesmos | |
| Li et al. | Cardiovascular benefits of native GLP-1 and its metabolites: an indicator for GLP-1-therapy strategies | |
| PH12020551024A1 (en) | Incretin analogs and uses thereof | |
| Martin et al. | Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25 | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| BR112018008805A8 (pt) | proteínas de função dupla e composição farmacêutica que compreende a mesma | |
| BR112015002080A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença | |
| AR077454A1 (es) | Preparaciones insulinicas que comprenden metionina | |
| Chae et al. | Beneficial effects of evogliptin, a novel dipeptidyl peptidase 4 inhibitor, on adiposity with increased Ppargc1a in white adipose tissue in obese mice | |
| Pathak et al. | Beneficial metabolic effects of dietary epigallocatechin gallate alone and in combination with exendin-4 in high fat diabetic mice | |
| CL2022002818A1 (es) | Análogos de glucagón como agonistas de acción prolongada del receptor de glp-1/glucagón | |
| Rolin et al. | The major glucagon-like peptide-1 metabolite, GLP-1-(9–36)-amide, does not affect glucose or insulin levels in mice | |
| BR112023016083A2 (pt) | Composições contendo análogos de incretina e seus usos | |
| BR112023022851A2 (pt) | Agonistas de receptor de peptídeo 1 similares ao glucagon macrocíclico | |
| EA202192296A1 (ru) | Терапевтическое применение дулаглутида | |
| Mesto et al. | P2-type purinergic signaling in the regulation of pancreatic β-cell functional plasticity as a promising novel therapeutic approach for the treatment of type 2 diabetes? | |
| BR112023027321A2 (pt) | Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo | |
| Schneider et al. | Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case study 2 | |
| CL2004002023A1 (es) | Formulacion, composicion y producto farmaceutico que comprende al menos un fijador al receptor y2 tal como pyy, npy o pp; agentes que aumentan su absorcion, para administrar por via mucosa y no infundida, usos para tratar obesidad. |